NCT06552117Not yet recruiting
ElastoMRI Evaluation of Hepatic Metastases in Colorectal Cancer ( MetaIRM)
ElastoMRI Evaluation of Hepatic Metastases in Colorectal Cancer
Source: ClinicalTrials.gov · Last updated 13 Aug 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Currently, the tumor response of operated colorectal liver metastases is assessed by histology of the resection specimen.The histological data make it possible to define categories (responder, partial responder, non-responder). Overall survival (OS: overall survival) after surgery crucially depends on the response to neoadjuvant chemotherapy. Current criteria for predicting histological response in preoperative imaging are not satisfactory. The working hypothesis is that it is possible to better differentiate the tissue response to conventional chemotherapies and anti-angiogenics through MRI elastography by quantifying the changes in tissue mechanical properties induced by systemic treatments. The objectives is to evaluate the mechanical properties obtained by elasto MRI according to the systemic treatments envisaged: conventional chemotherapy such as Folfox or combined with targeted therapy
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 30 Jul 2024
- Start date
- 10 Aug 2024
- Primary completion date
- 30 Oct 2026
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Diseases
- Colorectal cancer
- NCT number
- NCT06552117
What you commit to
- Study type: Interventional
- Planned participants: 50
- From 10 Aug 2024 to the primary completion date, 30 Oct 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients not affiliated with social security
- Pregnant or breastfeeding women
- Patients under guardianship, curatorship or safeguard of justice
- Patients with a contraindication to MRI or to the injection of contrast agent in MRI. The classic contraindications for MRI are defined by the French Society of Radiology:http://www.sfrnet.org/sfr/professionnels/1-fiche-information-patients/irm/index.phtml
- Lack of signed patient consent
Who the study is looking for
- Adult patients ≥18 years old, followed for colorectal cancer with hepatic metastases.
- The diagnosis of metastasis can be made: either by tumor biopsy or by the appearance during follow-up of colorectal cancer of at least one liver lesion with the characteristics of metastasis (fibrous tumor type imaging)
- Patient with an indication to receive first-line chemotherapy for liver metastases, whether or not associated with targeted therapy
- Patient with at least one hepatic metastasis greater than 2cm
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.